Loading clinical trials...
Loading clinical trials...
A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial
Conditions
Interventions
Leptin
Pioglitazone or metformin
+1 more
Locations
1
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Start Date
August 1, 2006
Primary Completion Date
May 1, 2011
Completion Date
June 1, 2011
Last Updated
March 23, 2017
NCT03039491
NCT00069004
NCT00627380
Lead Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions